Back to News
Market Impact: 0.4
Palisade Bio Gets FDA Clearance For PALI-2108 IND In Crohn's Disease
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Palisade Bio received FDA clearance for its IND application for PALI-2108, enabling clinical development in moderate-to-severe Crohn's disease. The clearance is a positive regulatory milestone for the clinical-stage biotech's inflammatory and fibrotic disease pipeline and could materially affect PALI shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
PALI0.80
More News
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Oil industry warns a diesel export ban will raise fuel prices as Trump weighs restrictions
- Australia says OpenAI agent hacked Medicare portal
- US aviation sanctions disrupt Iran flights, push travellers overland
- China Has Sensitive F-35 Parts Diverted to Hong Kong
- A US Diesel Export Ban Would Be a Calamity for the Market
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- 2026 Global Markets Outlook: Asset Allocation After the Great Disconnect
- Fintool Alternatives After the Microsoft Acquisition